Nanoliposomes in treatment of rheumatoid arthritis

doi:10.3760/cma.j.issn.1007-1245.2022.23.020

Abstract

Abstract: Rheumatoid arthritis is an autoimmune disease of unknown etiology. The typical pathological change is chronic synovitis, which significantly affects the patients' quality of life. Current drugs can relieve symptoms and delay the disease cours, but there are obvious adverse reactions. Nano-drug delivery systems represented by liposomes have shown obvious clinical advantages, and can improve the therapeutic effect of drugs through passive or active targeting. In this study, we review the role of liposomal drug delivery systems in the treatment of rheumatoid arthritis, describe their progress in preclinical studies and clinical trials, and discuss factors which may hinder their clinical translation.

Key words: Rheumatoid arthritis, Nano-drug delivery systems, Liposomes, Passive targeting, Active targeting

摘要： 类风湿性关节炎（RA）是一种病因未明的自身免疫性疾病，典型病理改变为慢性滑膜炎，严重影响患者生活质量。目前的治疗药物能够缓解症状，延缓病程，但均存在明显的不良反应。以脂质体为代表的纳米药物递送系统在临床上已显现出了明显的优势，其能够通过被动或主动靶向从而提高药物的治疗效应及减少不良反应。在本文中，我们回顾了脂质体药物递送系统在RA治疗中的作用，阐述了其在临床前研究和临床试验的进展，并讨论了可能阻碍其临床转化的因素。

关键词: 类风湿性关节炎, 纳米药物递送系统, 脂质体, 被动靶向, 主动靶向

Wang Jing, Zhu Meiyu, Kang Li, Han Juanjuan, Zhu Xuekai. Nanoliposomes in treatment of rheumatoid arthritis[J]. International Medicine and Health Guidance News, 2022, 28(23): 3337-.

王晶朱美玉康丽韩娟娟朱学凯. 纳米脂质体药物在类风湿性关节炎治疗中的研究进展[J]. 国际医药卫生导报, 2022, 28(23): 3337-.

References

[1] McInnes IB,Schett G.Pathogenetic insights from the treatment of rheumatoid arthritis[J].Lancet,2017,389(10086):2328-2337.DOI:10.1016/S0140-6736(17)31472-1.
[2] 杨贵兰,李文军,王春华.靶向脂质体的研究进展[J].药学研究,2020,39(5):289-293,307.DOI:10.13506/j.cnki.jpr.2020.05.010.
[3] 孙志坚,舒强. 类风湿关节炎合并骨质疏松症及骨折的研究进展[J].山东第一医科大学(山东省医学科学院)学报,2021,42(12):947-954.DOI:10.3969/j.issn.2097-0005.2021. 12.016.
[4] 谢文慧,张卓莉.类风湿关节炎成功治疗的核心理念和发展[J/CD].中国医学前沿杂志(电子版),2020,12(11):前插1,1-3.DOI:10.12037/YXQY.2020.11-01.
[5] 谢文慧,张卓莉.类风湿关节炎达标治疗:十年磨一剑[J].中华风湿病学杂志,2020,24(11):721-724.DOI:10.3760/cma.j.c141217-20201109-00222.
[6] Sparks JA.Rheumatoid arthritis[J].Ann Intern Med,2019,170(1):ITC1-ITC16.DOI:10.7326/AITC201901010.
[7] Luo D,Wang P,Lu F,et al.Mobile apps for individuals with rheumatoid arthritis:a systematic review[J].J Clin Rheumatol,2019,25(3):133-141.DOI:10.1097/RHU.0000000000000800.
[8] 张伟玲.关节腔内注射治疗类风湿关节炎的观察及临床护理分析[J/CD].临床医药文献电子杂志,2019,6(44):90.DOI:10.16281/j.cnki.jocml.2019.44.067.
[9] 胡胜涛,张二兵,林也,等.经皮给药纳米载体及靶向系统治疗类风湿关节炎研究进展[J].中国生物工程杂志,2021,41(2):98-106.DOI:10.13523/j.cb.2011013.
[10] 镇兰芳,镇东鑫.胶原诱导关节炎大鼠CD44和Fas/FasL的表达[J].青岛大学医学院学报,2014,50(2):130-132.DOI:10.13361/j.qdyxy.201402014.
[11] Xiao Q,Li X,Li Y,et al.Biological drug and drug delivery-mediated immunotherapy[J].Acta Pharm Sin B,2021,11(4):941-960.DOI:10.1016/j.apsb.2020.12.018.
[12] 苏云龙,王雪梅.99Tcm-3PRGD2对类风湿关节炎新生血管靶向受体显像的实验研究[J].中华核医学与分子影像杂志,2020(3):166-169.
[13] 任占芬,郑学军,罗寰,等.IL-17A、sICAM-1及sE-选择素与RA患者疾病活动度及疗效的关系[J].分子诊断与治疗杂志,2021,13(7):1098-1101,1105.DOI:10.3969/j.issn.1674-6929.2021.07.020.
[14] Li Y,Gu C,Liu G,et al.Polarization of rheumatoid macrophages is regulated by the CDKN2B-AS1/ MIR497/TXNIP axis[J].Immunol Lett,2021,239:23-31.DOI:10.1016/j.imlet.2021.08.001.
[15] 王建娜,成日青,萨仁高娃,等.脂质体作为药物载体的研究进展[J].中南药学,2019,17(9):1492-1498.DOI:10.7539/j.issn.1672-2981.2019.09.024.
[16] 许云华,张建,代英辉,等.纳米靶向技术在中药新型给药系统中的应用[J].中国药剂学杂志,2021,19(6):186-192.DOI:10.14146/j.cnki.cjp.2021.06.003.
[17] Kapoor B,Gulati M,Singh SK,et al.Fail-safe nano-formulation of prodrug of sulfapyridine: preparation and evaluation for treatment of rheumatoid arthritis[J].Mater Sci Eng C Mater Biol Appl,2021,118:111332.DOI:10.1016/j.msec.2020.111332.
[18] Srinath P,Vyas SP,Diwan PV.Preparation and pharmacodynamic evaluation of liposomes of indomethacin[J].Drug Dev Ind Pharm,2000,26(3):313-321.DOI:10.1081/ddc-100100359.
[19] 贾成友,张传辉,李微,等.抗类风湿关节炎中药经皮给药制剂研究进展[J].中国实验方剂学杂志,2015,21(16):226-230.DOI:10.13422/j.cnki.syfjx.2015160226.
[20] Garg NK,Tandel N,Bhadada SK,et al.Nanostructured lipid carrier-mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases[J].Front Pharmacol,2021,12:713616.DOI:10.3389/fphar.2021.713616.
[21] Song Y,Ismail M,Shan Q,et al.ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways[J].Nanoscale,2021,13(47):20170-20185.DOI:10.1039/d1nr05518f.
[22] Xue L,Wang D, Zhang X,et al.Targeted and triple therapy-based liposomes for enhanced treatment of rheumatoid arthritis[J].Int J Pharm,2020,586:119642.DOI:10.1016/j.ijpharm.2020.119642.
[23] Hu L,Luo X,Zhou S,et al.Neutrophil-mediated delivery of dexamethasone palmitate-loaded liposomes decorated with a sialic acid conjugate for rheumatoid arthritis treatment[J].Pharm Res,2019,36(7):97.DOI:10.1007/s11095-019-2609-4.
[24] de Ruiter MHT,Stijnis C,Nolte JW,et al.Fulminant presentation of oral mucosal leishmaniasis as severe stomatitis and periodontitis[J].Neth J Med,2018,76(1):40-42.
[25] Yu WJ,Huang DX,Liu S,et al.Polymeric nanoscale drug carriers mediate the delivery of methotrexate for developing therapeutic interventions against cancer and rheumatoid arthritis[J].Front Oncol,2020,10:1734.DOI:10.3389/fonc.2020.01734.
[26] Han D,Chen Q,Chen H.Food-derived nanoscopic drug delivery systems for treatment of rheumatoid arthritis[J].Molecules,2020,25(15):3506.DOI:10.3390/molecules 25153506.
[27] Fu Q,Gao Y,Zhao H,et al.Galangin protects human rheumatoid arthritis fibroblast‑like synoviocytes via suppression of the NF‑κB/NLRP3 pathway[J].Mol Med Rep,2018,18(4):3619-3624.DOI:10.3892/mmr.2018.9422.
[28] Meka RR,Venkatesha SH,Moudgil KD.Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis[J].J Control Release,2018,286:279-288.DOI:10.1016/j.jconrel.2018.08.007.
[29] 张鑫,刘颖,冯年平.载药金纳米粒的研究进展[J].药学实践杂志,2016,34(3):196-200,236.DOI:10.3969/j.issn.1006-0111.2016.03.002.
[30] 熊素彬,崔冬梅,王文喜,等.类风湿性关节炎的靶向给药系统研究进展[J].中国药学杂志, 2012, 47(1): 4-7.
[31] Kofoed Andersen C,Khatri S,Hansen J,et al.Carbon nanotubes-potent carriers for targeted drug delivery in rheumatoid arthritis[J].Pharmaceutics,2021,13(4):453.DOI:10.3390/pharmaceutics13040453.
[32] Song H,Wen J,Li H,et al.Enhanced transdermal permeability and drug deposition of rheumatoid arthritis via sinomenine hydrochloride-loaded antioxidant surface transethosome[J].Int J Nanomedicine,2019,14:3177-3188.DOI:10.2147/IJN.S188842.
[33] 周艺林,刘淑兰,夏新华,等.氧化还原敏感型靶向纳米给药系统的研究进展[J].中国新药杂志,2021,30(2):132-138.DOI:10.3969/j.issn.1003-3734.2021.02.007.
[34] 卓新雨,张艾立,马菲,等.纳米载药系统的研究进展[J].广东化工,2022,49(10):85-87.DOI:10.3969/j.issn.1007-1865.2022.10.026.